FELECIA MCBRIDE: Open Payments
NPI 1275956583 · BASSETT, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$716 in 39 payments from 13 companies in 2025. Trend: 2023 $425 · 2024 $617 · 2025 $716
Food & beverage: $716
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $147 |
| Corcept Therapeutics | 7 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Novo Nordisk Inc | 3 | $69 |
| Gilead Sciences, Inc. | 3 | $55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Lilly USA, LLC | 2 | $36 |
| Medtronic, Inc. | 1 | $35 |
| Alkermes, Inc. | 2 | $34 |
| Dexcom, Inc. | 1 | $25 |
Products named: Korlym, VRAYLAR, CAPLYTA, XIFAXAN, MOUNJARO, UBRELVY, SYNCHROMEDII, Dexcom G6 Transmitter.
Industry payments across VA — which companies pay providers there.
